Mean FSS scores returned to values comparable with baseline among patients receiving simeprevir/PR after Week 24 in PILLAR ( after treatment completion for the majority of patients ) and in ASPIRE ( after Week 48 ) , consistent with RGT enabling early termination of all treatment at Week 24 in 82.2 % of simeprevir/PR-treated patients in the PILLAR study .